<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605319</url>
  </required_header>
  <id_info>
    <org_study_id>0506007934</org_study_id>
    <secondary_id>2005-0202</secondary_id>
    <nct_id>NCT00605319</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia</brief_title>
  <acronym>Toviaz</acronym>
  <official_title>An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency
      with or without the inability to hold your urine until you get to the toilet) are invited to
      participate in this research study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overactive bladder is a common sequelae of long-term bladder outlet obstruction in men.
      Unfortunately, it does not often resolve after treatment of the obstruction (transurethral
      resection of the prostate). These patients are usually started empirically on alpha-blockers
      or occasionally anticholinergic agents, former used to treat enlarged prostate medically, and
      latter, to treat overactive bladder. We hypothesize that these patients would be
      significantly improved with a long-acting anticholinergic agent such as long acting
      Fesoterodine or Toviaz.

      Earlier studies have shown that anticholinergic drugs seem to have a beneficial effect on
      symptoms of patients with bladder outlet obstruction and overactive bladder. In addition,
      anticholinergic drug Toviaz is not associated with increased incidence of complication like
      acute urinary retention, a state where patient is unable to empty the bladder as an adverse
      effect of the drug.

      A large proportion of our patients that are undergoing treatment for bladder outlet
      obstruction also have overactive bladder. We propose an open label trial to evaluate the
      efficacy of Toviaz (fesoterodine) 4mg to 8 mg in patients that have continued symptoms of
      overactive bladder one month following transurethral resection of the prostate. Toviaz is an
      antimuscarinic and anticholinergic agent, and is a newer formulation of Detrol. Patients with
      overactive bladder on urodynamic test preoperatively will be considered. If these patients
      continue to have symptoms at the one-month post-operative visit, they will be enrolled into
      the study. We expect a total of 25 patients to be enrolled within 4 months. All patients will
      receive Toviaz 4mg to 8 mg. The patients will be followed at 3 months post-op, 4 months
      post-op, and 7 months post-op. At each post-op visit, the patients will fill out an AUA
      symptom score questionnaire, have noninvasive uroflowmetry performed, and have a post-void
      residual measured by bladder scan. Using standard statistical analysis, we will see if there
      is a difference in symptoms, post-void residual, or maximum flow rate between baseline and 7
      months post-op. We will continue the study to evaluate long-term efficacy, dropout rate, and
      complications. An FDA approved flexible dosing regimen will be allowed for the duration of
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPSS Obstructive</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with obstructive symptoms which includes hesitancy or difficulty initiating the stream, straining to void, a reduced flow, an intermittent stream or a sensation of incomplete emptying.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPSS Irritative</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with irritative symptoms which includes frequency, urgency, nocturia and urge incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPSS Nocturia</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with nocturia meaning individuals who wake up during sleeping hours to urinate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS) Quality of Life (QoL)</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>IPSS Quality of Life (QoL) is one question used to assess how the patient's symptoms affect their quality of life. A score ranges from 1 to 6, with 6 being the worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Flow Rate (Qmax)</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>Urodynamics was used to meause maximum flow rate (Qmax) which is the maximum recorded flow rate of urinary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Flow Rate (Qavg)</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>Average (mean) flow rate (Qavg) is the the volume of urine voided divided by the continuous flow time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postvoid Residual Volume (PVR)</measure>
    <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
    <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Bladder Outlet Obstruction</condition>
  <arm_group>
    <arm_group_label>Toviaz (Fesoterodine)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Toviaz 4mg to 8mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toviaz (Fesoterodine)</intervention_name>
    <description>4mg to 8mg by mouth once daily</description>
    <arm_group_label>Toviaz (Fesoterodine)</arm_group_label>
    <other_name>Toviaz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients will be selected by the investigator and sub-investigator's patient population,
        and physician referrals. All patients will meet the inclusion/ exclusion criteria.

        Inclusion Criteria

          1. Male â‰¥40 years of age

          2. Clinical signs and symptoms of frequency and urgency, enlarged prostate and urodynamic
             study consistent with overactive bladder.

          3. IPSS &gt;12, with IPSS QoL &gt; 3 at screening visit.

          4. Ability and willingness to correctly complete the micturition diary and all the trial
             related questionnaires comply with scheduled visits and comply with trial procedures.

          5. Capability of understanding and having signed the informed consent form after full
             discussion of the research, nature of the treatment, and its risks and benefits.

          6. Procedure to treat BOO by TURP or PVP greater than or equal to 1 month ago.

        Exclusion Criteria

          1. A known history of interstitial cystitis, uninvestigated hematuria, or bladder outlet
             obstruction due to: mullerian duct cysts, urethral obstruction due to
             stricture/valves/sclerosis of urethral tumor, radiation cystitis, genitourinary
             tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.

          2. Evidence of Urinary Tract Infection according to local standard of care.

          3. Expectation of initiating treatment during the duration of this study with - any drug
             treatment for OAB, any drugs with significant anticholinergic, antispasmodic,
             parasympathetic, or cholinergic agonistic effects.

          4. Use of any electrostimulation within the 30 days before randomization, or the
             expectation to initiate such therapy during the study.

          5. Any condition which, in the opinion of the investigator, makes the patient unstable,
             or with contraindications for inclusion, e.g., uncontrolled narrow-angled glaucoma,
             urinary retention, preplanned prostate surgery, or gastric retention.

          6. Significant hepatic or renal disease, defined as twice the upper limit of the
             reference ranges regarding serum concentrations of AST, ALT, ALP, urea nitrogen, or
             creatinine.

          7. Use of any other investigational drug in the 2 months preceding visit 1.

          8. History of postural hypotension or syncope in the judgement of the investigator based
             on local standards of care.

          9. Alcohol and/or any other drug abuse in the opinion of the investigator.

         10. Medications such as erythromycin, Biaxin (Clarithromycin), Sporanox (itraconazole),
             Nizoral (ketoconazole), Neoral and Sandimmune (cyclosporine), Velban (vinblastine) and
             miconazole.

         11. Non-medication treatments such as bio-feedback or other bladder training exercises.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Te, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Hospital, Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>March 17, 2017</results_first_submitted>
  <results_first_submitted_qc>March 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2018</results_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>BOO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder Neck Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Toviaz (Fesoterodine)</title>
          <description>Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Toviaz (Fesoterodine)</title>
          <description>Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" lower_limit="53" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" lower_limit="19.1" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Voided Volume</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86" lower_limit="20" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Laser</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TURP</title>
          <description>Transurethral Resection of the Prostate</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IPSS Obstructive</title>
        <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with obstructive symptoms which includes hesitancy or difficulty initiating the stream, straining to void, a reduced flow, an intermittent stream or a sensation of incomplete emptying.</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IPSS Obstructive</title>
            <description>Obstructive description
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPSS Obstructive</title>
          <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with obstructive symptoms which includes hesitancy or difficulty initiating the stream, straining to void, a reduced flow, an intermittent stream or a sensation of incomplete emptying.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPSS Irritative</title>
        <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with irritative symptoms which includes frequency, urgency, nocturia and urge incontinence</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IPSS Irritative</title>
            <description>Irritative description
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPSS Irritative</title>
          <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with irritative symptoms which includes frequency, urgency, nocturia and urge incontinence</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPSS Nocturia</title>
        <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with nocturia meaning individuals who wake up during sleeping hours to urinate.</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IPSS Nocturia</title>
            <description>Nocturia description
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPSS Nocturia</title>
          <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with nocturia meaning individuals who wake up during sleeping hours to urinate.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>International Prostate Symptom Score (IPSS) Quality of Life (QoL)</title>
        <description>IPSS Quality of Life (QoL) is one question used to assess how the patient's symptoms affect their quality of life. A score ranges from 1 to 6, with 6 being the worse outcome.</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IPSS QoL</title>
            <description>QoL description
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS) Quality of Life (QoL)</title>
          <description>IPSS Quality of Life (QoL) is one question used to assess how the patient's symptoms affect their quality of life. A score ranges from 1 to 6, with 6 being the worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Flow Rate (Qmax)</title>
        <description>Urodynamics was used to meause maximum flow rate (Qmax) which is the maximum recorded flow rate of urinary</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Qmax</title>
            <description>Qmax
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Flow Rate (Qmax)</title>
          <description>Urodynamics was used to meause maximum flow rate (Qmax) which is the maximum recorded flow rate of urinary</description>
          <units>mL/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Flow Rate (Qavg)</title>
        <description>Average (mean) flow rate (Qavg) is the the volume of urine voided divided by the continuous flow time</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QAvg</title>
            <description>QAvg
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Average Flow Rate (Qavg)</title>
          <description>Average (mean) flow rate (Qavg) is the the volume of urine voided divided by the continuous flow time</description>
          <units>mL/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">At the time that Qavg was collected, the Qavg data was skewed and was seen to be irrelevant and thus not reported for the screening appointment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postvoid Residual Volume (PVR)</title>
        <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
        <time_frame>screening (Month 0), 2-months, 3-months, 7-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-void Residual Volume (PVR)</title>
            <description>PVR
Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Postvoid Residual Volume (PVR)</title>
          <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Screening Month-0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the study period which was 7-months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Toviaz (Fesoterodine)</title>
          <description>Toviaz 4mg to 8mg
Toviaz (Fesoterodine): 4mg to 8mg by mouth once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation/Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Leakage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small Sample size and the nonrandomized and nonblinded administration of the drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alexis Te</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>646-962-4811</phone>
      <email>aet2005@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

